Registry following adults with chronic hand eczema during routine dermatology care
Collects long-term information on adults with chronic hand eczema and their treatments.
Key facts
- Who runs it
- CorEvitas
- Where
- Waltham, United StatesSee the site
- Trial code
- Registry title
- PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 21 Jul 2026
- Expected to end
- 31 Dec 2099
- Type of study
- Observational
- Treatments tested
- Observational (Non-Interventional) Registry
- Record updated
- 26 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for adults with moderate-to-severe chronic hand eczema who are starting a registry-listed medication under a dermatologist or other qualified provider.
- Age
- 18 years or older, and old enough to give legal consent where the research takes place.
- Sex
- All sexes can join.
- Disease stage
- Moderate-to-severe chronic hand eczema, diagnosed by a dermatologist or other qualified healthcare provider.
- Earlier treatment
- The person must be starting a medication that the registry accepts at the time of joining.
Main reasons for not taking part
- Taking part in, or planning to take part in, a blinded clinical trial for a chronic hand eczema drug
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- To be eligible to participate in this registry, an individual must meet all of the following criteria:; Diagnosed with moderate-to-severe CHE by a dermatologist or other qualified healthcare provider at the time of enrollment and initiating an eligible medication; Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment; Is willing and able to consent to participation in the registry; Is willing and able to complete registry-related forms electronically via personal devices; Is willing and able to provide the information (first name, last name, email address, language and primary time zone) required to create an account to allow you to complete registry forms via a personal device; Is willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip or postal code and email address or phone number at a minimum) if required based on registry location and applicable laws and regulations
Who cannot take part
- Is participating or planning to participate in a blinded clinical trial for a CHE drug
- An individual who meets any of the following criteria will be excluded from participation in the registry:
Where in United States
- CorEvitas, LLCWaltham, United StatesContact: Chronic Hand Eczema Registry TeamTaking people
About the trial
What the trial wants to find out
The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider. Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters using a structured and standardized data collection method
Treatments tested
- Observational (Non-Interventional) Registry
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry
- Plain-language title
- Registry following adults with chronic hand eczema during routine dermatology careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 August 2026